SARS-CoV-2 Mutation Detail Information

Virus Mutation SARS-CoV-2 Mutation I4205V


Basic Characteristics of Mutations
Mutation Site I4205V
Mutation Site Sentence Four additional mutations,one of them a coding mutation in orf1a (I4205V),were specific to B.1.429,while 3 additional mutations,including two coding mutations in orf1a (S3158T) and orf1b (P976L),were specific to B.1.427.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region ORF1a
Standardized Encoding Gene ORF1a  
Genotype/Subtype B.1.429
Viral Reference -
Functional Impact and Mechanisms
Disease Cell line    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location -
Literature Information
PMID 33991487
Title Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Author Deng X,Garcia-Knight MA,Khalid MM,Servellita V,Wang C,Morris MK,Sotomayor-Gonzalez A,Glasner DR,Reyes KR,Gliwa AS,Reddy NP,Sanchez San Martin C,Federman S,Cheng J,Balcerek J,Taylor J,Streithorst JA,Miller S,Sreekumar B,Chen PY,Schulze-Gahmen U,Taha TY,Hayashi JM,Simoneau CR,Kumar GR,McMahon S,Lidsky PV,Xiao Y,Hemarajata P,Green NM,Espinosa A,Kath C,Haw M,Bell J,Hacker JK,Hanson C,Wadford DA,Anaya C,Ferguson D,Frankino PA,Shivram H,Lareau LF,Wyman SK,Ott M,Andino R,Chiu CY
Journal Cell
Journal Info 2021 Jun 24;184(13):3426-3437
Abstract We identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the western United States. Named B.1.427/B.1.429 to denote its two lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced cases from September 2020 to January 2021, showing 18.6%-24% increased transmissibility relative to wild-type circulating strains. The variant carries three mutations in the spike protein, including an L452R substitution. We found 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation common to variants B.1.1.7, B.1.351, and P.1. Antibody neutralization assays revealed 4.0- to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California exhibiting decreased antibody neutralization warrants further investigation.
Sequence Data MW972466-MW974550
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.